At least three different clinical trials with DNMT inhibitors genistein (NCT00244933, NCT00290758, NCT00099008) and HDAC inhibitor curcumin (NCT01042938, NCT01740323, NCT02556632) have been completed on breast cancer patients. The gene discussed is DNMT1; the disease is breast carcinoma.